Fundraising Fox
Mike Scott
Chief Development Officer at Aspect Biosystems
Fremont, California, United States
Find your path to Mike
Sign up to see every warm intro you have to Mike
- Paths you didn't know you had: your email and LinkedIn already hold routes to Mike. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Mike Scott is Chief Development Officer at Aspect Biosystems, where he leads the development of cellular medicines that combine therapeutic cells with 3D bioprinting and hypoimmune cell engineering, guiding them toward regulatory approval and clinical trials. His prior work spans cell therapies, medical devices, and combination products across therapeutic areas including Parkinson's disease, heart failure, diabetes, and eye diseases, with roles at Novo Nordisk, BlueRock, ViaCyte, Edwards Lifesciences, and Orqis Medical. At Edwards Lifesciences, he served as Manager of Advanced Heart Valve Therapy Technologies and led a cross-functional team that brought a bioprosthetic valve to market in the European Union and Canada in 2002 and the U.S. in 2003.
Frequently asked questions
- Who is Mike Scott?
- Mike Scott is Chief Development Officer at Aspect Biosystems, where he leads the development of cellular medicines that combine therapeutic cells with 3D bioprinting and hypoimmune cell engineering, guiding them toward regulatory approval and clinical trials. His prior work spans cell therapies, medical devices, and combination products across therapeutic areas including Parkinson's disease, heart failure, diabetes, and eye diseases, with roles at Novo Nordisk, BlueRock, ViaCyte, Edwards Lifesciences, and Orqis Medical. At Edwards Lifesciences, he served as Manager of Advanced Heart Valve Therapy Technologies and led a cross-functional team that brought a bioprosthetic valve to market in the European Union and Canada in 2002 and the U.S. in 2003.
About this profile. Compiled from public sources — the organisations' own websites and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights